Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients

Experimental and Clinical Immunogenetics

Volumn 14, Issue 4, 1998, Pages 264-272

  Kittl, E M ^a   Ruckser, R ^b   Selleny, S ^b   Samek, V ^c   Hofmann, J ^a   Huber, K ^a   Reiner, A ^c   Ogris, E ^c   Hinterberger, W ^b   Bauer, K ^a  

^a Institute of Laboratory Medicine   (Austria)

^b 2nd Department of Medicine   (Austria)

^c NONE   (Austria)

Author keywords

Breast cancer; sCD44v5; Serum

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST DISEASE; BREAST METASTASIS; CANCER DIAGNOSIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SMOKING;

ALTERNATIVE SPLICING; ANTIGENS, CD44; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 6844250123     PISSN: 02549670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with the extracellular matrix. Adv Immunol 1993;54:271-335.
2. Underhili C: The hyaluronan receptor. J Cell Sci 1992;103:293-298.
3. Haynes BF, Liao HX, Patton KL: The transmembrane hyaluronate receptor (CD44): Multiple functions, multiple forms. Cancer Cells 1991; 9:347-350.
4. Gunthert U: CD44: A multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993; 184:47-63.
5. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-12164.
6. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U: Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
7. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KD, Harris AL, Gearing A, Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994; 54:4539-4546.
8. Wirth K, Arch R, Somasundaram C, Hofmann M, Weber B, Herrlich P, Matzku S, Zöller M: Expression of CD44 isoforms carrying metastasis-associated sequences in newborn and adult rats. Eur J Cancer 1993; 29A:1172-1177.
9. Terpe HJ, Stark H, Prehm P, Günthert U: CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 1994;101:79-89.
10. Gunthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
11. Reber S, Matzku S, Gunthert U, Ponta H, Herrlich P, Zoller M: Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer 1990;46:919-927.
12. Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H, Herrlich H, Gunthert U: CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-5297.
13. Woodman AC, Sugiyama M, Yoshida K, Sugino T, Borgya A, Goodison S, Matsumura Y, Tarin D: Analysis of anomalous CD44 gene expression in human breast, bladder and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996;149:1519-1530.
14. Koopman G, Griffioen AW, Ponta H, Herrlich P, Van den Berg F, Manten HE, Pals ST: CD44 variants; expression on lymphocytes and in neoplasia. Res Immunol 1993; 144:750-754.
15. Herrlich P, Zöller M, Pals ST, Ponta H: CD44 splice variants: Metastases meet lymphocytes. Immunol Today 1993;14:395-399.
16. Zöller M: CD44: Physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med 1995;73:425-438.
17. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993;143:867-874.
18. Tempfer C, Losch A, Heinzl H, Hausler G, Hanzal E, Kolbl H, Breitenecker G, Kainz C: Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996;32: 2023-2025.
19. Wielenga VJM, Heider KH, Offerhaus JA, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-4756.
20. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I, Johnson JP: De novo expression of CD44 and survival in gastric cancer. Lancet 1993;342:1019-1022.
21. Joensuu H, Ristamaki R, Klemi PJ, Jalkanan S: Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer 1993;68:428-432.
22. Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;350:1053-1058.
23. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;65:422-426.
24. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C: Immunohistochemical and serological evaluation of CE44 splice variants in human ovarian cancer. Br J Cancer 1995;72:1494-1497.
25. Kittl EM, Ruckser R, Rech-Weichselbraun I, Hinterberger W, Bauer K: Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Eur J Clin Chem Clin Biochem 1997;35: 81-84.
26. McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW: Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996;98:2403-2413.
27. Kittl EM, Haberhauer G, Ruckser R, Selleny S, Rech-Weichselbraun I, Hinterberger W, Bauer K: Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol Int 1997;16:181-186.
28. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T: Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988;58:213-215.
29. Ruibal A, Colomer R, Genolla J: Prognostic value of CA 15-3 serum levels in patients having breast cancer. Horm Metab 1987;1:11-15.
30. ASCO Expert Panel T: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol 1996;14:2843-2877.